Actimmune Related Published Studies
Well-designed clinical trials related to Actimmune (Interferon Gamma-1B)
Low-dose recombinant canine interferon-gamma for treatment of canine atopic dermatitis: an open randomized comparative trial of two doses. [2010.02]
Immunomodulation with recombinant interferon-gamma1b in pulmonary tuberculosis. [2009.09.15]
Effect of interferon gamma-1b on survival in patients with idiopathic pulmonary fibrosis (INSPIRE): a multicentre, randomised, placebo-controlled trial. [2009.07.18]
Endogenous blood maximal interferon-gamma production may predict response to interferon-gamma 1beta treatment in patients with idiopathic pulmonary fibrosis. [2009.07]
Randomized phase 3 trial of interferon gamma-1b plus standard carboplatin/paclitaxel versus carboplatin/paclitaxel alone for first-line treatment of advanced ovarian and primary peritoneal carcinomas: results from a prospectively designed analysis of progression-free survival. [2008.05]
Adjuvant interferon gamma in patients with pulmonary atypical Mycobacteriosis: a randomized, double-blind, placebo-controlled study. [2008.02.11]
Double-blind trial of recombinant gamma-interferon versus placebo in the treatment of rheumatoid arthritis. 1989. [2008.02]
Final results of a double-blind, placebo-controlled trial of the antifibrotic efficacy of interferon-gamma1b in chronic hepatitis C patients with advanced fibrosis or cirrhosis. [2007.03]
A randomized comparative clinical trial of recombinant canine interferon-gamma (KT-100) in atopic dogs using antihistamine as control. [2006.06]
Randomized, double-blind, placebo-controlled, dose-escalating study of aerosolized interferon gamma-1b in patients with mild to moderate cystic fibrosis lung disease. [2005.03]
Effects of interferon-gamma 1b on biomarker expression in patients with idiopathic pulmonary fibrosis. [2004.07.15]
Recombinant interferon- gamma 1b as adjunctive therapy for AIDS-related acute cryptococcal meningitis. [2004.06.15]
Th1 cytokine pattern (IL-12 and IL-18) in bronchoalveolar lavage fluid (BALF) before and after treatment with interferon gamma-1b (IFN-gamma-1b) or colchicine in patients with idiopathic pulmonary fibrosis (IPF/UIP). [2004.06]
A placebo-controlled trial of interferon gamma-1b in patients with idiopathic pulmonary fibrosis. [2004.01.08]
Recombinant gamma interferon stimulates signal transduction and gene expression in alveolar macrophages in vitro and in tuberculosis patients. [2003.04]
Interferon-gamma administration does not affect human thyroid hormone metabolism in the post-surgical euthyroid sick syndrome. [2002.04]
Intravesical instillations of interferon gamma in the prophylaxis of high risk superficial bladder cancer--results of a controlled prospective study. [2002]
Double-blind prospective randomized comparison of interferon gamma-1b versus placebo after autologous stem cell transplantation. [2002]
Perioperative treatment with human recombinant interferon-gamma: a randomized double-blind clinical trial. [2001.11]
A phase III study of recombinant human interferon gamma to prevent opportunistic infections in advanced HIV disease. [2001.06.10]
Placebo-associated remissions in a multicentre, randomized, double-blind trial of interferon gamma-1b for the treatment of metastatic renal cell carcinoma. The Canadian Urologic Oncology Group. [2000.10]
A randomized phase II trial comparing two different sequence combinations of autologous vaccine and human recombinant interferon gamma and human recombinant interferon alpha2B therapy in patients with metastatic renal cell carcinoma: clinical outcome and analysis of immunological parameters. [2000.04]
A preliminary study of long-term treatment with interferon gamma-1b and low-dose prednisolone in patients with idiopathic pulmonary fibrosis. [1999.10.21]
Immunochemotherapy with interferon-gamma and multidrug therapy for multibacillary leprosy. [1999.03.15]
Conditioned immune response to interferon-gamma in humans. [1999.02]
Changes in cytokine production of breast cancer patients treated with interferons. [1998.12]
Interferon gamma-1b compared with placebo in metastatic renal-cell carcinoma. Canadian Urologic Oncology Group. [1998.04.30]
Interferon-gamma in the prevention of severe burn-related infections: a European phase III multicenter trial. The Severe Burns Study Group. [1998.03]
Role of recombinant interferon-gamma maintenance in responding patients with small cell lung cancer. A randomised phase III study of the EORTC Lung Cancer Cooperative Group. [1997.10]
Response to interferon-gamma plus pentavalent antimony in Indian visceral leishmaniasis. [1997.10]
Dose-dependent enhancements by interferon-gamma on functional responses of neutrophils from chronic granulomatous disease patients. [1997.05.01]
A randomized, double-blind study comparing twenty-four-week treatment with recombinant interferon-gamma versus placebo in the treatment of rheumatoid arthritis. [1997.01]
Effect of interferon-gamma, in vitro and in vivo, on mRNA levels of phagocyte oxidase components. [1996.12]
Keloid excision and recurrence prophylaxis via intradermal interferon-gamma injections: a pilot study. [1996.12]
Interferon gamma in trauma-related infections. [1996.10]
Phase II study of interferon-gamma versus interleukin-2 and interferon-alpha 2b in metastatic renal cell carcinoma. [1996.02]
Immunochemotherapy for a systemic intracellular infection: accelerated response using interferon-gamma in visceral leishmaniasis. [1995.04]
Recombinant human interferon-gamma in patients with chronic granulomatous disease--European follow up study. [1995.04]
EORTC (30885) randomised phase III study with recombinant interferon alpha and recombinant interferon alpha and gamma in patients with advanced renal cell carcinoma. The EORTC Genitourinary Group. [1995.02]
Safety and effectiveness of long-term interferon gamma therapy in patients with chronic granulomatous disease. [1995]
Efficacy trial of topically administered interferon gamma-1 beta gel in comparison to laser treatment in cervical intraepithelial neoplasia. [1995]
Phase III trial of recombinant interferon gamma in complete responders with small-cell lung cancer. [1994.11]
Randomised, controlled study of intratumoral recombinant gamma-interferon treatment in newly diagnosed glioblastoma. [1994.07]
Efficacy of a short course (10 days) of high-dose meglumine antimonate with or without interferon-gamma in treating cutaneous leishmaniasis in Guatemala. [1994.03]
Interferon gamma administration increases monocyte HLA-DR antigen expression but not endogenous interferon production. [1994.02]
Interferons combined with chemotherapy in the treatment of stage III-IV non-small cell lung cancer--a randomised study. [1994]
Immune response induced in small-cell lung cancer by maintenance therapy with interferon gamma. [1993.11.17]
Prospective 5-year followup of recombinant interferon-gamma in rheumatoid arthritis. [1993.11]
Treatment of steroid-dependent asthma with recombinant interferon-gamma. [1993.09]
Immunochemotherapy for visceral leishmaniasis: a controlled pilot trial of antimony versus antimony plus interferon-gamma. [1993.05]
Alpha- and gamma-interferon versus alpha-interferon alone in chronic hepatitis B. A randomized controlled study. [1993.03]
Recombinant interferon gamma therapy for atopic dermatitis. [1993.02]
Long-term treatment of chronic myelogenous leukemia with different interferons: results from three studies. [1993.01]
Recombinant human interferon gamma in the treatment of rheumatoid arthritis: double blind placebo controlled study. [1992.09]
Clinical study with recombinant interferon gamma versus interferon alpha-2c in patients with condylomata acuminata. [1992.09]
Treatment with interferon gamma versus interferons alfa and gamma in children with chronic hepatitis B. [1992.08]
Treatment of patients with chronic granulomatous disease with recombinant human interferon-gamma does not improve neutrophil oxidative metabolism, cytochrome b558 content or levels of four anti-microbial proteins. [1992.05]
Increase in neutrophil Fc gamma receptor I expression following interferon gamma treatment in rheumatoid arthritis. [1992.04]
A randomized prospective clinical trial to determine the efficacy of interferon-gamma in severely injured patients. [1992.02]
A prospective randomized comparison of single-agent interferon (IFN)-alpha with the combination of IFN-alpha and low-dose IFN-gamma in chronic myelogenous leukaemia. [1992.02]
Interferon gamma-1b. A review of its pharmacology and therapeutic potential in chronic granulomatous disease. [1992.01]
Enhanced serum levels of soluble HLA class I molecules are induced by treatment with recombinant interferon-gamma (IFN-gamma). [1991.11]
Phase II trial of recombinant DNA gamma-interferon in advanced colorectal cancer: a Southwest Oncology Group study. [1991.10]
A randomised controlled trial of recombinant interferon-gamma in Chinese patients with chronic hepatitis B virus infection. [1991.07]
In vivo interferon-gamma therapy augments the in vitro ability of chronic granulomatous disease neutrophils to damage Aspergillus hyphae. [1991.04]
A randomized trial comparing a pentavalent antimonial drug and recombinant interferon-gamma in the local treatment of cutaneous leishmaniasis. [1991.03]
High doses of recombinant alpha-interferon or gamma-interferon for chronic hepatitis C: a randomized, controlled trial. [1991.02]
Phase II evaluation of recombinant gamma-interferon in patients with advanced pancreatic carcinoma: a Southwest Oncology Group study. [1990.12]
Efficacy of interferons on bowenoid papulosis and other precancerous lesions. [1990.12]
A controlled trial of intralesional recombinant interferon-gamma in the treatment of keloidal scarring. Clinical and histologic findings. [1990.10]
Recombinant gamma-interferon as adjuvant to hepatitis B vaccine in hemodialysis patients. [1990.10]
Treatment of cancer patients with recombinant interferon-gamma induces release of endogenous tumor necrosis factor-alpha. [1990.06]
In vivo biological response to recombinant interferon-gamma during a phase I dose-response trial in patients with metastatic melanoma. [1990.06]
Lack of suppression of IgE production by recombinant interferon gamma: a controlled trial in patients with allergic rhinitis. [1990.05]
Acute effects of single doses of recombinant interferon-gamma on blood cell counts and lymphocyte subsets in patients with advanced renal cell cancer. [1989.08]
Double-blind trial of recombinant gamma-interferon versus placebo in the treatment of rheumatoid arthritis. [1989.08]
Antiviral effect of recombinant gamma interferon in chronic hepatitis B virus infection: a pilot study. [1988.02]
Results of a multicenter placebo-controlled double-blind randomized phase III clinical study of treatment of rheumatoid arthritis with recombinant interferon-gamma. [1988]
Well-designed clinical trials possibly related to Actimmune (Interferon Gamma-1B)
Six-minute-walk test in idiopathic pulmonary fibrosis: test validation and minimal clinically important difference. [2011.05.01]
Clinical and laboratory study of pro-inflammatory and antiinflammatory cytokines in women with multiple sclerosis. [2011.04]
An adjuvanted polyprotein HIV-1 vaccine induces polyfunctional cross-reactive CD4+ T cell responses in seronegative volunteers. [2011.02.15]
Vaccination with a modified vaccinia virus Ankara (MVA)-vectored HIV-1 immunogen induces modest vector-specific T cell responses in human subjects. [2010.10.21]
An HIV-1 clade A/E DNA prime, recombinant fowlpox virus boost vaccine is safe, but non-immunogenic in a randomized phase 1/11a trial in Thai volunteers at low risk of HIV infection. [2010.10.08]
An HIV-1 clade A/E DNA prime, recombinant fowlpox virus boost vaccine is safe, but non-immunogenic in a randomized phase I/IIa trial in Thai volunteers at low risk of HIV infection. [2010.10]
Safety and immunogenicity study of Multiclade HIV-1 adenoviral vector vaccine alone or as boost following a multiclade HIV-1 DNA vaccine in Africa. [2010.09.21]
Vaccine-induced IgG2 anti-HIV p24 is associated with control of HIV in patients with a 'high-affinity' FcgammaRIIa genotype. [2010.08.24]
Recombinant Liver Stage Antigen-1 (LSA-1) formulated with AS01 or AS02 is safe, elicits high titer antibody and induces IFN-gamma/IL-2 CD4+ T cells but does not protect against experimental Plasmodium falciparum infection. [2010.07.12]
Ag85B-ESAT-6 adjuvanted with IC31 promotes strong and long-lived Mycobacterium tuberculosis specific T cell responses in naive human volunteers. [2010.04.30]
A phase 1/2 study of a multiclade HIV-1 DNA plasmid prime and recombinant adenovirus serotype 5 boost vaccine in HIV-Uninfected East Africans (RV 172). [2010.02.15]
Effect of thymosin-alpha(1) on T-helper 1 cell and T-helper 2 cell cytokine synthesis in patients with hepatitis B virus e antigen-positive chronic hepatitis B. [2010]
Changes in Trypanosoma cruzi-specific immune responses after treatment: surrogate markers of treatment efficacy. [2009.12.01]
A Phase 1 study to evaluate the safety and immunogenicity of a recombinant HIV type 1 subtype C-modified vaccinia Ankara virus vaccine candidate in Indian volunteers. [2009.11]
Cell-mediated immunity elicited by the blood stage malaria vaccine apical membrane antigen 1 in Malian adults: results of a Phase I randomized trial. [2009.03.26]
Short-term anti-CD25 monoclonal antibody administration down-regulated CD25 expression without eliminating the neogenetic functional regulatory T cells in kidney transplantation. [2009.03]
A prime/boost DNA/Modified vaccinia virus Ankara vaccine expressing recombinant Leishmania DNA encoding TRYP is safe and immunogenic in outbred dogs, the reservoir of zoonotic visceral leishmaniasis. [2009.02.11]
Effect of anluohuaxian tablet combined with gamma-IFN on schistosomal liver fibrosis. [2009.02]
Phase 1/2a study of the malaria vaccine candidate apical membrane antigen-1 (AMA-1) administered in adjuvant system AS01B or AS02A. [2009]
Enhanced CBir1-specific innate and adaptive immune responses in Crohn's disease. [2008.12]
A new recombinant bacille Calmette-Guerin vaccine safely induces significantly enhanced tuberculosis-specific immunity in human volunteers. [2008.11.15]
Effects of recombinant human growth hormone on HIV-1-specific T-cell responses, thymic output and proviral DNA in patients on HAART: 48-week follow-up. [2008.10.31]
Safety and immunogenicity of an intramuscular Helicobacter pylori vaccine in noninfected volunteers: a phase I study. [2008.09]
|
